Health-Related Quality of Life and Survival in Metastasized Non-Small Cell Lung Cancer Patients with and without a Targetable Driver Mutation

SIMPLE SUMMARY: NSCLC patients with a targetable driver mutation are entitled to receive targeted therapy. Targeted therapy is usually less toxic than chemotherapy and immunotherapy. However, low-grade side effects are common and often chronic, which could also negatively impact a patient’s health-r...

Descripción completa

Detalles Bibliográficos
Autores principales: Billingy, Nicole E., Tromp, Vashti N. M. F., van den Hurk, Corina J. G., Becker-Commissaris, Annemarie, Walraven, Iris
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8428358/
https://www.ncbi.nlm.nih.gov/pubmed/34503092
http://dx.doi.org/10.3390/cancers13174282

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8428358/
https://www.ncbi.nlm.nih.gov/pubmed/34503092
http://dx.doi.org/10.3390/cancers13174282

Ejemplares similares